Meet the Engineers
144 views · Published 5 October 2015 · 1:25 · Indexed 19 October 2026
Channel: MultiVu · 2015 · Science & Technology
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months. The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers. To view the multimedia release go to: http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
More from this channel
-
2:24
Nespresso by KitchenAid
-
0:53
Best Skincare & Makeup Reviews
-
5:01
AARP Magazine With Sheryl Crow and Melissa Etheridge
-
1:57
Concentrix Flagship Delivery Center
-
1:09
Casino Gaming’s Economic Impact
-
2:00
Anchor it and Protect a Child
-
2:42
The PowerHaul Locomotive Platform
-
0:31
New PSA aims to bridge opportunity divide